By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb ...
Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...
Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...
Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.